Antibodies against human or mouse IL-21 receptor

Details Antibodies against human or mouse IL-21 receptor Antibodies against human or mouse IL-21 receptor

2004-03-12

2009-02-24

Bunner, Bridget E (Department: 1647)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S388230, C530S389200, C530S391300, C424S139100, C424S143100, C435S069100

Reexamination Certificate

active

07495085

ABSTRACT:
The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4495285 (1985-01-01), Shimizu et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 6057128 (2000-05-01), Donaldson et al.
patent: 6258562 (2001-07-01), Salfeld et al.
patent: 6307024 (2001-10-01), Novak et al.
patent: 6350892 (2002-02-01), Banville et al.
patent: 6576744 (2003-06-01), Presnell et al.
patent: 2001/0025022 (2001-09-01), Kikly et al.
patent: 2002/0090680 (2002-07-01), Hodge
patent: 2002/0128446 (2002-09-01), Novak et al.
patent: 2002/0137677 (2002-09-01), Sprecher et al.
patent: 2002/0160451 (2002-10-01), Masiakowski et al.
patent: 2003/0049798 (2003-03-01), Carter et al.
patent: 2003/0108549 (2003-06-01), Carter et al.
patent: 2003/0148447 (2003-08-01), Presnell et al.
patent: 0 388 151 (1990-09-01), None
patent: 0 812 913 (1997-12-01), None
patent: 1 088 831 (2001-04-01), None
patent: 27241282 (1996-03-01), None
patent: WO 87/05330 (1987-09-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 96/04388 (1996-02-01), None
patent: WO 97/47741 (1997-12-01), None
patent: WO 97/47742 (1997-12-01), None
patent: WO 98/11225 (1998-03-01), None
patent: WO 98/31811 (1998-07-01), None
patent: WO 99/47675 (1999-09-01), None
patent: WO 00/08152 (2000-02-01), None
patent: WO 00/17235 (2000-03-01), None
patent: WO 00/27882 (2000-05-01), None
patent: WO 00/53761 (2000-09-01), None
patent: WO 00/56772 (2000-09-01), None
patent: WO 00/69880 (2000-11-01), None
patent: WO0069880 (2000-11-01), None
patent: WO 01/36467 (2001-05-01), None
patent: WO 01/55112 (2001-08-01), None
patent: WO 01/77171 (2001-10-01), None
patent: WO 01/85792 (2001-11-01), None
patent: WO0202641 (2002-01-01), None
patent: WO 03/028630 (2003-04-01), None
Immunology, fifth edition Janeway et al., eds., Garland Publishing, New York, 2001, ISBN 081533642 X, chapter 3 and Glossary.
Altschul et al., “Basic Local Alignment Search Tool”,J. Mol. Biol., 215:403-410 (1990).
Aplin et al., “Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids”,CRC Crit. Rev. Biochem., 10:259-306 (1981).
Asao et al., “Cutting Edge: The Common γ-Chain Is an Indispensable Subunit of the IL-21 Receptor Complex”,J. Immunol., 167:1-5 (2001).
Barbas et al., “In Vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity”,Proc. Natl. Acad. Sci. USA, 91:3809-3813 (1994).
Baumgartner et al., “Double Blind, Placebo Controlled Trial of Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) in Active Rheumatoid Arthritis”,J. Invest. Med., 44(3):235A (1996).
Bazan, “Structural design and molecular evolution of a cytokine receptor superfamily,”Proc. Natl. Acad. Sci. USA, 87:6934-6938 (1990).
Bird et al., “Single-Chain Antigen-Binding Proteins”,Science, 242:423-426 (1988).
Biró et al., “The effect to WSEWS Pentapeptide and WSEWS-Specific Monoclonal Antibodies on Constitutive and IL-6 Induced Acute-Phase Protein Production by a Human Hepatoma Cell Line, HEPG-2,”Immunology Letters, 46:183-187 (1995).
Caput et al., “Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α Chain,”J. Biol. Chem., 271(28)16921-16926 (1996).
Chikanza et al., “Treatment of Patients with Rheumatoid Arthritis with RP73401 Phosphodiesterase Type IV Inhibitor”,Arthritis&Rheumatism, 39(9):S282, Abstract 1527 (1996).
Clackson et al., “Making Antibody Fragments Using Phage Display Libraries”,Nature, 352:624-628 (1991).
Courtenay et al., “Immunisation Against Heterologous Type II Collagen Induces Arthritis in Mice”,Nature, 283:666-628 (1980).
D'Andrea et al., “Expression Cloning of the Murine Erythropoietin Receptor,”Cell, 57:277-285 (1989).
Debinski et al., “A Novel Chimeric Protein Composed of Interleukin 13 andPseudomonasExotoxin Is Highly Cytotoxic to Human Carcinoma Cells Expressing Receptors for Interleukin 13 and Interleukin 4,”J. Biol. Chem., 270(28):16775-16780 (1995).
Dusanter-Fourt et al., “Transduction du signal par les récepteurs de cytokines,”Synthése, 10:825-35 (1994); English language summary attached.
Edge et al., “Deglycosylation of Glycoproteins by Trifluoromethanesulfonic Acid”,Anal. Biochem., 118:131-137 (1981).
Ehrich et al., “Demonstration of Selective Cox-2 Inhibition by MK-966 In Humans”,Arthritis&Rheumatism, 39(9):S81, Abstract 328 (1996).
Elit, L., “CCI-779 Wyeth”,Curr. Opin. Invest. Drugs, 3:1249-1253 (2002).
Engström, A., “The Arrangement of the Protein Molecules in Nuclear-Polyhedrosis Inclusions”,Biochem. Exp. Biol., 11:7-13 (1974).
Evans et al., “Efficacy of Tumor Necrosis Factor Binding Protein (TNF-bp) In the Streptococcal Cell Wall-Induced Reactivation Model of Arthritis”,Arthritis&Rheumatism, 39(9):S284, Abstract 1540 (1996).
Farr et al., “Sulphasalazine (SASP) in Rheumatoid Arthritis (RA): A 5 Year Prospective Study”,Arthritis&Rheumatism, 39(9):S281, Abstract 1519 (1996).
Fiebich et al., “Effects of NSAIDs on IL-1 β Induced IL-6 mRNA and Protein Synthesis in Human Astrocytoma Cells”,Neuroimmunol., 7:1209-1213 (1996).
Finnegan et al., “Leflunomide Inhibits Immunoglobulin Production by Two Separate Mechanisms”,Arthritis&Rheumatism, 39(9):S131, Abstract 627 (1996).
Fulmer et al., “Transplantation of Cardiac Tissue into the Mouse Ear”,Am. J. Anatomy, 113:273-281 (1963).
Gram et al., “In VitroSelection and Affinity Maturation of Antibodies from a Naive Combinatorial Immunoglobulin Library”,Proc. Natl. Acad. Sci. USA, 89:3576-3580 (1992).
Griffiths et al., “Human Anti-Self Antibodies with High Specificity From Phage Display Libraries”,EMBO J., 12:725-734 (1993).
Guttadauria, M., “Tenidap in Rheumatoid Arthritis Collaborative International Study (Tracis): A 6-Month Interim Analysis”,Arthritis&Rheumatism, 39(9):S280, Abstract 1516 (1996).
Hatakeyama et al., “Interleukin-2 Receptor Chain Gene: Generation of Three Receptor Forms by Cloned Human and Chain cDNA's,”Science, 244:552-556 (1989).
Hieter et al., “Clustered Arrangement of Immunogloublin λ Constant Region Genes in Man”,Nature, 294:536-540 (1981).
Hillier et al., “Generation and analysis of 280,000 human expressed sequence tags,”Genome Res., 6(9):807-828 (1996).
Holmdahl et al., “The Molecular Pathogenesis of Collagen-Induced Arthritis in Mice—A Model for Rheumatoid Arthritis”,Ageing Res. Rev., 1:135-147 (2002).
Huang et al., “Inhibitors of Mammalian Target of Rapamycin as Novel Antitumor Agents: From Bench to Clinic”,Curr. Opin. Investig. Drugs, 3:

Affiliated with

Also associated with

Rating

Antibodies against human or mouse IL-21 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies against human or mouse IL-21 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against human or mouse IL-21 receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4132137